INSIGHTS ON DRUG DEVELOPMENT

• Corticosteroids And Hormonal Therapies — History, Use, And Future Outlook

  Explore how evolving science, expanding global demand, and next-generation innovations are reshaping the future of corticosteroid and hormonal therapies — and what this transformation means for the years ahead.

• Polymorphism 101: What Early-Stage Drug Developers Need To Know To Reduce Risk

  Polymorphism impacts solubility, stability, and manufacturability, making early solid‑form screening critical to reduce risk, guide development decisions, and ensure consistent performance.

• What Will It Take To Make MCED And MRD A Reality?

  Cancer mortality is declining, but the need for earlier action remains. Gain insight into how MCED and MRD are advancing cancer detection and surveillance, helping clinicians identify disease sooner.

• Unlocking Robust Separations For Modern Peptide Therapeutics

  As peptide therapeutics grow more complex, impurity profiling demands greater chromatographic confidence. See how robust reproducibility can support reliable GLP-1 receptor agonist analysis.

• Column Selection For RPLC-UV Impurity Analysis

  7/17/2025

  Explore the performance of four column chemistries for RPLC-UV impurity analysis of liraglutide and semaglutide, which offers practical guidance for method development in peptide-based therapeutics.

• Why CDMO Performance Drops Exactly When It Matters Most

  6/15/2026

  Programs often stall moving to GMP due to fragmented workflows and knowledge gaps. Aligning teams and integrating development with execution, via continuous data, sustains momentum and reduces risk.

• Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery

  6/3/2025

  Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.

• Improving Therapeutic Protein Efficacy Through Charge Profile Adjustment

  9/10/2024

  By adequately measuring charge variants early in development and implementing effective control strategies, developers can mitigate risks and ensure the safety and efficacy of their mAb products.

• Collaboration An Untapped Fuel For Driving Biopharma R&D

  10/20/2025

  Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.